CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles

Cited by papers we hold 4

• Engineered transfer RNAs for suppression of premature termination codons · 2019
  No notice
• Microhomologies are prevalent at Cas9-induced larger deletions · 2019
  No notice
• In utero nanoparticle delivery for site-specific genome editing · 2018
  No notice
• CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.